Vitamin E therapy for NAFLD/NASH
My colleagues and I read with great interest the recent article by Ji and colleagues reporting the effect of vitamin E on serum aminotransferase levels in patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and chronic hepatitis C, evaluated by meta-analysis [1]. NAFLD is increasingly recognized as a common cause of chronic liver diseases in association with the current epidemic prevalence of obesity and diabetes mellitus in the general population. NAFLD is now regarded as a manifestation of metabolic syndrome and the link between obesity, diabetes mellitus, cardiovascular disease and NAFLD is likely to reflect shared pathogenic factors.
Source: Nutrition - Category: Nutrition Authors: Masashi Yoneda, Takenao Hasegawa, Ken Sato Tags: Letter to the Editor Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Heart | Hepatitis | Hepatitis C | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Urology & Nephrology | Vitamin E | Vitamins